Titlebook: Mechanical Circulatory Support for Advanced Heart Failure; A Texas Heart Instit Jeffrey A. Morgan,Andrew B. Civitello,O.H. Frazier Book 201

代替

溝通

Who Is an Appropriate Candidate for Long-Term MCS?: The Art of Patient Selection,t is the leading cause of morbidity and mortality, with 50% mortality within 5?years of diagnosis [.]. Approximately less than 10% of this population will progress to advanced HF. These patients experience poor quality of life, frequent hospitalizations, and a 1-year mortality of 25–50% [2, 3]. Adva

Expand

cochlea

獨(dú)白

貿(mào)易

LVAD Surgical Implant Technique: Infradiaphragmatic Approach, Despite the evolution to continuous flow devices, this technique has remained popular. However, an apical location can make patients vulnerable to arrhythmias and obstruction due to interaction with the ventricular septum. We developed a method for implanting the HeartMate II, HVAD, and HM3 LVAD al

Pageant

stressors

寬度

Management of Fluid Balance and Perioperative Renal Complications,ure. Renal and liver dysfunctions often improve after left ventricular assist device placement, but complications in the postoperative period—especially hemodynamic instability, considerable blood loss and blood product replacement, prolonged cardiopulmonary bypass time, right heart failure, and inc

下邊深陷

Chronic Management of Patients with Left Ventricular Assist Devices,g this event, the FDA approved implantable LVADs in 1994 as a bridge to transplantation. Due to a perpetual shortage of available organ donors for end-stage congestive heart failure (CHF) patients, durable LVAD implantation is now also used for destination therapy (DT) since 2002 after it received a